ATAI — AtaiBeckley Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 2081043 ·
Last close
$3.84
Market Cap
$1.41B
52W High
$5.51
52W Low
$3.27
ADV30
4,876,194
Next earnings
2026-08-13
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 954,000 -30,159,000 -29,782,000 264,877,000 43,102,000 66,098,000
Dec 2025 1,066,000 -39,353,000 -544,813,000 292,723,000 85,300,000 70,722,000
Sep 2025 749,000 -28,407,000 -61,074,000 239,820,000 30,402,000 79,912,000
Jun 2025 719,000 -25,245,000 -27,729,000 189,204,000 61,940,000 45,279,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-105,924,000
Investing CF
$-119,766,000
Financing CF
$210,697,000
CapEx
$-10,868,000
Dividends Paid
Buybacks
$-4,468,000
EPS Diluted TTM
$-2.23
As of
2026-06-07

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,390,036,000
Inventory
Receivables
$14,709,000
ST Investments
$187,665,000
EBIT TTM
$-663,060,000
Pretax Income TTM
$-663,322,000
Interest Exp TTM
$262,000
Analysts
12

Yahoo Snapshot (yfinance, live)

Total Revenue
$3,488,000
EBITDA
$-121,896,000
Free Cash Flow
$-55,528,624
Enterprise Value
$1,188,227,072
Total Cash
$230,767,008
Total Debt
$5,138,000
Shares Out
368,166,674
Trailing EPS
$-2.84
Book Value
$0.56
ROE
-378.0%
ROA
-33.3%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 4,089,000 -113,347,000 -660,047,000 292,723,000 70,722,000 -102,675,000
Dec 2024 308,000 -102,166,000 -149,269,000 159,387,000 42,833,000 -82,437,000
Dec 2023 314,000 -123,026,000 -40,224,000 293,478,000 49,162,000 -84,118,000
Dec 2022 233,000 -144,430,000 -152,385,000 305,441,000 39,675,000 -104,467,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.46

Max Pain — expiry 2026-06-18

max pain strike: $4.00 · spot: $4.32 · call oi: 9,887 · put oi: 2,092
Expected Move to 2026-06-18: ±$0.40 (9.27%) — implied range $3.92$4.72 · ATM straddle on $4.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
MLTX MoonLake Immunotherapeutics $1.41B $19.19
AVBP ArriVent BioPharma, Inc. $1.41B $30.30
BCAX Bicara Therapeutics Inc. $1.42B $21.56
ARDX ARDELYX, INC. $1.40B $5.68
GHRS GH Research PLC $1.40B $20.37

News headlines (Yahoo Finance, 1h cache)

Wall Street Bullish on AtaiBeckley (ATAI), Here’s Why
2026-06-16 18:45 · Yahoo
Is AtaiBeckley Inc. (ATAI) the Hidden Penny Stock to Invest In?
2026-06-13 15:30 · Yahoo
Atai Beckley N.V. (ATAI) A Top Penny Stock to Buy Poised to Build Sustained Clinical and Shareholder Value
2026-06-07 17:57 · Yahoo
AtaiBeckley nears key clinical catalysts, Jefferies stays positive with repeat ‘Buy’ rating
2026-06-04 17:38 · Yahoo
Is AtaiBeckley’s BPL-003 Phase 3 Launch Altering The Investment Case For AtaiBeckley (ATAI)?
2026-06-04 06:11 · Yahoo
Assessing AtaiBeckley (ATAI) Valuation After Strong Returns And Elevated Price To Book Ratio
2026-06-04 02:12 · Yahoo
AtaiBeckley launches mental health patient impact grant program
2026-05-28 13:57 · Yahoo
AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations
2026-05-28 13:00 · Yahoo
AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026
2026-05-27 10:00 · Yahoo
AtaiBeckley (ATAI) Reports Q1 Financial Results
2026-05-22 18:43 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.